Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

Compare

1,030 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GPCR Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Structure

Therapeutics, Inc. Sponsored ADR

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GPCR Stock 12 Month Forecast

Average Price Target

$72.90

▲(289.01% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Structure Therapeutics, Inc. Sponsored ADR in the last 3 months. The average price target is $72.90 with a high forecast of $100.00 and a low forecast of $44.00. The average price target represents a 289.01% change from the last price of $18.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","101":"$101","35.75":"$35.8","57.5":"$57.5","79.25":"$79.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,35.75,57.5,79.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,23.92923076923077,30.268461538461537,36.607692307692304,42.94692307692307,49.28615384615384,55.62538461538462,61.964615384615385,68.30384615384615,74.64307692307692,80.98230769230769,87.32153846153845,93.66076923076923,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,21.844615384615384,26.099230769230772,30.353846153846156,34.60846153846154,38.863076923076925,43.11769230769231,47.3723076923077,51.62692307692308,55.88153846153847,60.136153846153846,64.39076923076924,68.64538461538463,{"y":72.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,19.62153846153846,21.653076923076924,23.684615384615384,25.716153846153844,27.747692307692308,29.779230769230768,31.810769230769232,33.84230769230769,35.87384615384615,37.90538461538462,39.93692307692308,41.96846153846154,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$72.90

Lowest Price Target$44.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

$100

Buy

433.62%

Upside

Reiterated

08/11/25

BMO Capital Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Ananda Ghosh

H.C. Wainwright

$60

Buy

220.17%

Upside

Reiterated

08/08/25

H.C. Wainwright Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

David Risinger

Leerink Partners

$60→$44

Buy

134.79%

Upside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink

Jonathan Wolleben

Citizens JMP

$89→$87

Buy

364.25%

Upside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $87 from $89 at Citizens JMPStructure Therapeutics price target lowered to $87 from $89 at Citizens JMP

Annabel Samimy

Stifel Nicolaus

$50

Buy

166.81%

Upside

Reiterated

08/07/25

Stifel Nicolaus Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Seamus Fernandez

Guggenheim

$92→$90

Buy

380.26%

Upside

Reiterated

08/06/25

Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim

Andy Hsieh

William Blair

―

Buy

―

Reiterated

08/06/25

Promising Developments in Structure Therapeutics' Clinical Trials Drive Buy Rating

Kaveri Pohlman

Clear Street

$61

Buy

225.51%

Upside

Initiated

07/30/25

Structure Therapeutics initiated with a Buy at Clear StreetStructure Therapeutics initiated with a Buy at Clear Street

Prakhar Agrawal

Cantor Fitzgerald

$65

Buy

246.85%

Upside

Reiterated

06/22/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

Roger Song

Jefferies

$79

Buy

321.56%

Upside

Reiterated

06/05/25

Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating

Yasmeen Rahimi

Piper Sandler

$93

Buy

396.26%

Upside

Reiterated

06/03/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Piper Sandler

Terence Flynn

Morgan Stanley

$118→$120

Buy

540.34%

Upside

Reiterated

05/12/25

Structure Therapeutics (GPCR) PT Raised to $120 at Morgan StanleyMorgan Stanley analyst Terence Flynn raised the price target on Structure Therapeutics (NASDAQ: GPCR) to $120.00 (from $118.00) while maintaining a Overweight rating.

Myriam Belghiti

LifeSci Capital

$83

Buy

342.90%

Upside

Reiterated

05/09/25

Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning

Samantha Semenkow

Citi

$60

Buy

220.17%

Upside

Initiated

05/02/25

Buy Recommendation for Structure Therapeutics: Promising Pipeline and Obesity Treatment Market Potential

Dex Genotek

TR | OpenAI - 4o

―

Sell

―

Reiterated

04/20/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

$100

Buy

433.62%

Upside

Reiterated

08/11/25

BMO Capital Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Ananda Ghosh

H.C. Wainwright

$60

Buy

220.17%

Upside

Reiterated

08/08/25

H.C. Wainwright Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

David Risinger

Leerink Partners

$60→$44

Buy

134.79%

Upside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink

Jonathan Wolleben

Citizens JMP

$89→$87

Buy

364.25%

Upside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $87 from $89 at Citizens JMPStructure Therapeutics price target lowered to $87 from $89 at Citizens JMP

Annabel Samimy

Stifel Nicolaus

$50

Buy

166.81%

Upside

Reiterated

08/07/25

Stifel Nicolaus Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Seamus Fernandez

Guggenheim

$92→$90

Buy

380.26%

Upside

Reiterated

08/06/25

Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim

Andy Hsieh

William Blair

―

Buy

―

Reiterated

08/06/25

Promising Developments in Structure Therapeutics' Clinical Trials Drive Buy Rating

Kaveri Pohlman

Clear Street

$61

Buy

225.51%

Upside

Initiated

07/30/25

Structure Therapeutics initiated with a Buy at Clear StreetStructure Therapeutics initiated with a Buy at Clear Street

Prakhar Agrawal

Cantor Fitzgerald

$65

Buy

246.85%

Upside

Reiterated

06/22/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

Roger Song

Jefferies

$79

Buy

321.56%

Upside

Reiterated

06/05/25

Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating

Yasmeen Rahimi

Piper Sandler

$93

Buy

396.26%

Upside

Reiterated

06/03/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Piper Sandler

Terence Flynn

Morgan Stanley

$118→$120

Buy

540.34%

Upside

Reiterated

05/12/25

Myriam Belghiti

LifeSci Capital

$83

Buy

342.90%

Upside

Reiterated

05/09/25

Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning

Samantha Semenkow

Citi

$60

Buy

220.17%

Upside

Initiated

05/02/25

Buy Recommendation for Structure Therapeutics: Promising Pipeline and Obesity Treatment Market Potential

Dex Genotek

TR | OpenAI - 4o

―

Sell

―

Reiterated

04/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+7.06%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +7.06% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+8.49%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +8.49% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

6/17 ratings generated profit

Average Return

-7.06%

reiterated a buy rating 7 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -7.06% per trade.

2 Years

xxx

Success Rate

2/17 ratings generated profit

Average Return

-37.12%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -37.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GPCR Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GPCR has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GPCR average Analyst price target in the past 3 months is 72.90.

Each month's total comprises the sum of three months' worth of ratings.

GPCR Financial Forecast

GPCR Earnings Forecast

Next quarter’s earnings estimate for GPCR is -$0.37 with a range of -$0.43 to -$0.28. The previous quarter’s EPS was -$0.36. GPCR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.67% of the time in the same period. In the last calendar year GPCR has Outperformed its overall industry.

No data currently available

GPCR Sales Forecast

Next quarter’s sales forecast for GPCR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. GPCR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 37.98% of the time in the same period. In the last calendar year GPCR has Preformed in-line its overall industry.

GPCR Stock Forecast FAQ

What is GPCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 72.90.

What is GPCR’s upside potential, based on the analysts’ average price target?

Structure Therapeutics, Inc. Sponsored ADR has 289.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GPCR a Buy, Sell or Hold?

Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Structure Therapeutics, Inc. Sponsored ADR’s price target?

The average price target for Structure Therapeutics, Inc. Sponsored ADR is 72.90. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $44.00. The average price target represents 289.01% Increase from the current price of $18.74.

What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?

Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of GPCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

GPCR Analyst Ratings

GPCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

GPCR Analyst Recommendation Trends

GPCR Financial Forecast

GPCR Earnings Forecast

GPCR Sales Forecast

GPCR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts